Lovaza Sales Data
| Rank 59 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Lovaza U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 59 ( 1) |
$258,177 | 2.90% | 1,336 | -5.05% |
| Q3 2013 | 58 (8) |
$250,893 | -4.96% | 1,407 | -8.81% |
| Q2 2013 | 50 ( 2) |
$263,998 | -1.47% | 1,543 | -1.72% |
| Q1 2013 | 52 (1) |
$267,926 | 0.70% | 1,570 | -4.33% |
| Q4 2012 | 51 (2) |
$266,067 | -0.19% | 1,641 | -0.42% |
| Q3 2012 | 53 (7) |
$266,568 | 8.82% | 1,648 | 6.39% |
| Q2 2012 | 60 (7) |
$244,963 | 2.13% | 1,549 | 0.78% |
| Q1 2012 | 67 (1) |
$239,845 | -1.81% | 1,537 | -4.53% |
| Q4 2011 | 68 (1) |
$244,272 | 5.34% | 1,610 | 2.88% |
| Q3 2011 | 67 (9) |
$231,896 | -8.96% | 1,565 | -8.75% |
| Q2 2011 | 58 (7) |
$254,718 | 3.98% | 1,715 | 4.00% |
| Q1 2011 | 65 | $244,967 | n/a | 1,649 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
